跳至主要内容
临床试验/JPRN-jRCT1080221967
JPRN-jRCT1080221967已完成4 期

The post-marketing clinical randomized study of eldecalcitol on fall-related physical performance in Japanese osteoporotic patients with frailty

Chugai Pharmaceutical Co., Ltd.0 个研究点目标入组 124 人开始时间: 2012年11月19日最近更新:

试验速览

阶段
4 期
状态
已完成
入组人数
124

研究概览

简要总结

A randomized, open-label, controlled clinical trial has been conducted with 124 female patients aged 65 or over with osteoporosis. Patients were randomly assigned to receive either 0.75 mcg of ELD once-a-day or 35 mg of ALN once-a-week for 24 weeks. The primary endpoint was the change in a postural balance index, adjusted composite equilibrium score (CES) of sensory organization test (SOT). There was no statistically significant difference between the two groups.

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 65age old 至 ot applicable(—)
性别
Female

入选标准

  • Osteoporosis patients with normal walking speed is within between 0.5m/sec and 1.2m/sec.

排除标准

  • Patients: those take psychotropic agents, or anabolic agents, etc., and those physical performances are diagnosed to be influenced by above agents. Patients received agents that affect bone metabolism within 8 weeks before the treatment start.
  • Patients with disease(s) accompanied by high risk of falls except for osteoporosis.
  • Patients with disease(s) characterized by low bone mass except for osteoporosis.

研究者

相似试验